Register entry
- Registered sites
- 0
- Active NDC listings
- 22
- Live patents
- 273
- Exclusivities
- 4
- Countries
- 0
Catalogue
Drug listings by form and route
2222 active NDC listings: 22 human prescription drug. By marketing category: NDA 14, BLA 8.
| Dosage form | NDCs |
|---|---|
| tablet | 8 |
| injection | 6 |
| tablet, extended release | 5 |
| injection, powder, lyophilized, for solution | 2 |
| cream | 1 |
| Route | NDCs |
|---|---|
| oral | 13 |
| intravenous | 8 |
| topical | 1 |
| Labeller name on the listing | NDCs |
|---|---|
| incyte corporation | 22 |
Exclusivity
Patents and exclusivities
273| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 10639310 | OPZELURAruxolitinib phosphate | use | Dec 2026 |
| 11744832 | JAKAFI XRruxolitinib phosphate | use | Dec 2026 |
| 8530485 | JAKAFI XRruxolitinib phosphate | product | Dec 2026 |
| 9079912 | JAKAFI, JAKAFI XR, OPZELURAruxolitinib phosphate | use | Dec 2026 |
| 9206187 | JAKAFI XRruxolitinib phosphate | use | Dec 2026 |
| 9814722 | JAKAFI, JAKAFI XRruxolitinib phosphate | use | Dec 2026 |
| 9974790 | OPZELURAruxolitinib phosphate | use | Dec 2026 |
| 10639310*PED | OPZELURAruxolitinib phosphate | use | Jun 2027 |
| 9079912*PED | JAKAFI, OPZELURAruxolitinib phosphate | use | Jun 2027 |
| 9814722*PED | JAKAFIruxolitinib phosphate | use | Jun 2027 |
| 9974790*PED | OPZELURAruxolitinib phosphate | use | Jun 2027 |
| 7598257 | JAKAFI, JAKAFI XR, OPZELURAruxolitinib phosphate | substance, product | Dec 2027 |
| 8415362 | JAKAFI, JAKAFI XR, OPZELURAruxolitinib phosphate | substance, product | Dec 2027 |
| 10016429 | JAKAFI, JAKAFI XRruxolitinib phosphate | use | Jun 2028 |
| 10610530 | OPZELURAruxolitinib phosphate | use | Jun 2028 |
| 11213528 | JAKAFI XRruxolitinib phosphate | product | Jun 2028 |
| 8722693 | JAKAFI, JAKAFI XR, OPZELURAruxolitinib phosphate | substance, product | Jun 2028 |
| 8822481 | JAKAFI, JAKAFI XR, OPZELURAruxolitinib phosphate | use | Jun 2028 |
| 8829013 | JAKAFI, JAKAFI XRruxolitinib phosphate | use | Jun 2028 |
| 7598257*PED | JAKAFI, JAKAFI XR, OPZELURAruxolitinib phosphate | use | Jun 2028 |
| 8415362*PED | JAKAFI, JAKAFI XR, OPZELURAruxolitinib phosphate | use | Jun 2028 |
| 10016429*PED | JAKAFI, JAKAFI XRruxolitinib phosphate | use | Dec 2028 |
| 10610530*PED | OPZELURAruxolitinib phosphate | use | Dec 2028 |
| 11213528*PED | JAKAFI XRruxolitinib phosphate | use | Dec 2028 |
| 8722693*PED | JAKAFI, JAKAFI XR, OPZELURAruxolitinib phosphate | use | Dec 2028 |
| 8822481*PED | JAKAFI, JAKAFI XR, OPZELURAruxolitinib phosphate | use | Dec 2028 |
| 8829013*PED | JAKAFI, JAKAFI XRruxolitinib phosphate | use | Dec 2028 |
| 10758543 | OPZELURAruxolitinib phosphate | product | May 2031 |
| 10869870 | OPZELURAruxolitinib phosphate | use | May 2031 |
| 11219624 | OPZELURAruxolitinib phosphate | product | May 2031 |
| 11571425 | OPZELURAruxolitinib phosphate | product | May 2031 |
| 11590136 | OPZELURAruxolitinib phosphate | use | May 2031 |
| 12226419 | OPZELURAruxolitinib phosphate | product | May 2031 |
| 12544381 | OPZELURAruxolitinib phosphate | product | May 2031 |
| 12564593 | OPZELURAruxolitinib phosphate | product | May 2031 |
| 10758543*PED | OPZELURAruxolitinib phosphate | use | Nov 2031 |
| 10869870*PED | OPZELURAruxolitinib phosphate | use | Nov 2031 |
| 11219624*PED | OPZELURAruxolitinib phosphate | use | Nov 2031 |
| 10874616 | JAKAFI XRruxolitinib phosphate | product | Nov 2033 |
| 11576864 | JAKAFI XRruxolitinib phosphate | use | Nov 2033 |
| 11576865 | JAKAFI XRruxolitinib phosphate | product | Nov 2033 |
| 11896717 | JAKAFI XRruxolitinib phosphate | product | Nov 2033 |
| 11337927 | JAKAFI XRruxolitinib phosphate | use | Jan 2034 |
| 10131667 | PEMAZYREpemigatinib | use | Apr 2034 |
| 10874616*PED | JAKAFI XRruxolitinib phosphate | use | May 2034 |
| 11576864*PED | JAKAFI XRruxolitinib phosphate | use | May 2034 |
| 11576865*PED | JAKAFI XRruxolitinib phosphate | use | May 2034 |
| 11896717*PED | JAKAFI XRruxolitinib phosphate | use | May 2034 |
| 11337927*PED | JAKAFI XRruxolitinib phosphate | use | Jul 2034 |
| 9611267 | PEMAZYREpemigatinib | substance, product | Jan 2035 |
| 11466004 | PEMAZYREpemigatinib | use | May 2039 |
| 11590138 | OPZELURAruxolitinib phosphate | use | Jun 2040 |
| 12233067 | OPZELURAruxolitinib phosphate | use | Jul 2040 |
| 11628162 | PEMAZYREpemigatinib | use | Aug 2040 |
| 11510923 | OPZELURAruxolitinib phosphate | use | Sept 2040 |
| 11590137 | OPZELURAruxolitinib phosphate | use | Sept 2040 |
| 12589096 | OPZELURAruxolitinib phosphate | use | Sept 2040 |
| 12552792 | PEMAZYREpemigatinib | substance, product | Oct 2040 |
| 11602536 | OPZELURAruxolitinib phosphate | use | May 2041 |
| Product | Exclusivity | Until |
|---|---|---|
| JAKAFIRUXOLITINIB PHOSPHATE | PED Paediatric | Mar 2029 |
| JAKAFI XRRUXOLITINIB PHOSPHATE | PED Paediatric | Mar 2029 |
| OPZELURARUXOLITINIB PHOSPHATE | NPP New patient population | Sept 2028 |
| PEMAZYREPEMIGATINIB | ODE-404 Orphan drug | Aug 2029 |
Catalogue
Marketed products
22| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| JAKAFI | ruxolitinib | tablet, oral | 50881-005NDA |
| JAKAFI | ruxolitinib | tablet, oral | 50881-010NDA |
| JAKAFI | ruxolitinib | tablet, oral | 50881-015NDA |
| JAKAFI | ruxolitinib | tablet, oral | 50881-020NDA |
| JAKAFI | ruxolitinib | tablet, oral | 50881-025NDA |
| JAKAFI XR | ruxolitinib | tablet, extended release, oral | 50881-011NDA |
| JAKAFI XR | ruxolitinib | tablet, extended release, oral | 50881-022NDA |
| JAKAFI XR | ruxolitinib | tablet, extended release, oral | 50881-033NDA |
| JAKAFI XR | ruxolitinib | tablet, extended release, oral | 50881-044NDA |
| JAKAFI XR | ruxolitinib | tablet, extended release, oral | 50881-055NDA |
| MONJUVI | Tafasitamab-cxix | injection, powder, lyophilized, for solution, intravenous | 50881-013BLA |
| MONJUVI | Tafasitamab-cxix | injection, powder, lyophilized, for solution, intravenous | 73535-208BLA |
| NIKTIMVO | axatilimab-csfr | injection, intravenous | 50881-012BLA |
| NIKTIMVO | axatilimab-csfr | injection, intravenous | 50881-023BLA |
| NIKTIMVO | axatilimab-csfr | injection, intravenous | 50881-034BLA |
| NIKTIMVO | axatilimab-csfr | injection, intravenous | 50881-036BLA |
| NIKTIMVO | axatilimab-csfr | injection, intravenous | 50881-047BLA |
| OPZELURA | ruxolitinib | cream, topical | 50881-007NDA |
| PEMAZYRE | pemigatinib | tablet, oral | 50881-026NDA |
| PEMAZYRE | pemigatinib | tablet, oral | 50881-027NDA |
| PEMAZYRE | pemigatinib | tablet, oral | 50881-028NDA |
| ZYNYZ | retifanlimab-dlwr | injection, intravenous | 50881-006BLA |
Compare
Other companies listing ruxolitinib
- Catalent Pharma Solutions Inc.22 sites · 261 NDC
Enquiry
Common questions
- Is Incyte Corporation FDA approved?
- Incyte Corporation holds no registered establishment of its own; 22 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Incyte Corporation make?
- 22 products are listed under Incyte Corporation in the openFDA NDC Directory, most often as tablet; injection; tablet, extended release. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.